Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

High-Affinity α 5 β 1 -Integrin-Selective Bicyclic RGD Peptides Identified via Screening of Designed Random Libraries.

Bernhagen D., Jungbluth V., Gisbert Quilis N., Dostalek J., White PB., Jalink K.

Laboratory Study, published in ACS Comb Sci (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
ACS Comb Sci (2019)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
31269394
DOI
10.1021/acscombsci.9b00081
Citations
12

Abstract (original English)

We report the identification of high-affinity and selectivity integrin α 5 β 1 -binding bicyclic peptides via "designed random libraries", that is, the screening of libraries comprising the universal integrin-binding sequence Arg-Gly-Asp (RGD) in the first loop in combination with a randomized sequence (XXX) in the second loop. Screening of first-generation libraries for α 5 β 1 -binding peptides yielded a triple-digit nanomolar bicyclic α 5 β 1 -binder ( C T3 RGD c T3 AYG C T3 , IC 50 = 406 nM). Next-generation libraries were designed by partially varying the structure of the strongest first-generation lead inhibitor and screened for improved affinities and selectivities for this receptor. In this way, we identified three high-affinity α 5 β 1 -binders ( C T3 RGD c T3 AYJ C T3 , J = d-Leu, IC 50 = 90 nM; C T3 RGD c T3 AYa C T3 , IC 50 = 156 nM; C T3 RGD c T3 AWG C T3 , IC 50 = 173 nM), of which one even showed a higher α 5 β 1 -affinity than the 32 amino acid benchmark peptide knottin-RGD (IC 50 = 114 nM). Affinity for α 5 β 1 -integrin was confirmed by SPFS analysis showing a K d of 4.1 nM for Cy5-labeled RGD-bicycle C T3 RGD c T3 AYJ C T3 (J = d-Leu) and a somewhat higher K d (9.0 nM) for Cy5-labeled knottin-RGD. The α 5 β 1 -bicycles, for example, C T3 RGD c T3 AYJ C T3 (J = d-Leu), showed excellent selectivities over α v β 5 (IC 50 ratio α 5 β 1 /α v β 5 between <0.009 and

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Combinatorial Chemistry TechniquesOligopeptidesPeptide LibraryReceptors, Vitronectin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.